Fig. 6: VDAC2 expression inversely correlates with glioma grades and predicts outcome of glioma patients.

a, b Representative IHC images (a) and quantification of IHC scores (b) of VDAC2 in human gliomas with grade II, grade III, and grade IV (GBM) (**p < 0.01, *p < 0.05). c VDAC2 mRNA level in human gliomas with grade II, grade III, and grade IV (GBM) from the TCGA database (***p < 0.001). d Kaplan–Meier analysis of VDAC2 expression and overall survival of glioma patients (n = 60) from Southwest Hospital. e, f Kaplan–Meier analysis of VDAC2 expression and overall survival of GBM patients (n = 515) from TCGA database (e) or those (n = 188) from Gravendeel database (f). X-tile software is used to determine the cutoff point of VDAC2 expression for the survival analysis